References:
- Hers I, Vincent EE, Tavaré JM. Akt signalling in health and disease.Cell Signal. 2011; 23: 1515-27. doi:
10.1016/j.cellsig.2011.05.004
- Fischer-Posovszky P, Tews D, Horenburg S, Debatin KM, Wabitsch M.
Differential function of Akt2 and Akt2 in human adipocytes. Mol.
Cell. Endocrinol. 2012; 358: 135-143. doi:
10.1016/j.mce.2012.03.018
- Wan M, Leavens KF, Saleh D, Easton RM, Guertin DA, Peterson TR,
Kaestner KH, Sabatini DM, Birnbaum MJ. Postprandial lipid metabolism
requires signaling through Akt2 independent of the transcription
factors FoxA2, FoxO1, SREBP1c. Cell Metab. 2011; 14: 516-527.
doi:10.1016/j.cmet.2011.09.001.
- Arya VB, Flanagan SE, Schober E, Rami-Merhar B, Ellard S, Hussain K.
Activating AKT2 mutation: hypoinsulinemic hypoketotic hypoglycemia.J Clin Endocrinol Metab. 2014; 99(2): 391-4. doi:
10.1210/jc.2013-3228.
- Dushar M, Nowaczyk J, Pyrzak B, Akopyan H, Smigiel R, Walczak A,
Rydzanicz M, Ploski R, Szczaluba K. Efficacy and safety of sirolimus
therapy in familial hypoinsulinemic hypoglycemia caused by AKT2
mutation inherited from the mosaic father. Med Genet. 2021;
64(12). doi: 10.1016/j.ejmg.2021.104368.
- Garg N, Bademci G, Foster J 2nd, Sıklar Z, Berberoglu M, Tekin M.
MORFAN Syndrome: An Infantile Hypoinsulinemic Hypoketotic Hypoglycemia
Due to an AKT2 Mutation. J Pediatr. 2015; 167(2): 489-91. doi:
10.1016/j.jpeds.2015.04.069.
- Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A,
Scott C, Harris J, Smillie BJ, Savage DB, Ramaswami U, De Lonlay P,
O’Rahilly S, Barroso I, Semple RK. An activating mutation of AKT2 and
human hypoglycemia. Science. 2011;334(6055):474. doi:
10.1126/science.1210878.
- Ochoa Molina MF, Poggi H, De Toro V, Mendoza C, Hussain K. Facial
Dysmorphic Features in a Patient With Nonketotic Hypoglycemia and a
Pathogenic Variant in the AKT2 Gene. AACE Clin Case Rep.2021;8(3):109-112. doi: 10.1016/j.aace.2021.11.006.
- Hijazi G, Pai N, Nagy LL, et al. Use of waxy maize heat modified
starch in the treatment of children between 2 and 5 years with
glycogen storage disease type I: A retrospective study. Mol
Genet Metab Rep. 2019; 21:1-6. doi:
10.1016/j.ymgmr.2019.100536
- Ferrara C, Patel P, Becker S, Stanley CA, Kelly A. Biomarkers of
Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants
and Children. J Pediatr. 2016 Jan;168:212-219. doi:
10.1016/j.jpeds.2015.09.045.
- White MF. The insulin signalling system and the IRS protein.Diabetologia . 1997; 40: S2-S17. doi: 10.1007/s001250051387
- Hemmings BA & Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring
Harb Perspect Biol. 2012; 4(9). doi: 10.1101/cshperspect.a011189.
- Banerjee I, Salomon-Estebanez M, Shah P, Nicholson J, Cosgrove KE,
Dunne MJ. Therapies and outcomes of congenital hyperinsulinism-induced
hypoglycaemia. Diabet Med. 2019; 36(1): 9-21. doi:
10.1111/dme.13823.
- Minic M, Rocha N, Harris J, et al. Constitutive Activation of AKT2 in
Humans Leads to Hypoglycemia Without Fatty Liver or Metabolic
Dyslipidemia. J Clin Endocrinol Metab. 2017;102(8):2914-2921.
doi: 10.1210/jc.2017-00768.
- Steinkrauss L, Lipman TH, Hendell CD, Gerdes M, Thornton PS, Stanley
CA. Effects of hypoglycemia on developmental outcome in children with
congenital hyperinsulinism. J. Pediatr. Nurs. 2005; 20(2);
109-118.
- Parker VER, Keppler-Noreuil KM, Faivre L, et al. Safety and efficacy
of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.Genet Med . 2019; 21:1189-1198. doi: 10.1038/s41436-018-0297-9
- Szymanowski M, Estebanez MS, Padidela R, et al. mTOR inhibitors for
the treatment of severe congenital hyperinsulinism: Perspectives on
limited therapeutic success. J Clin Endocrinol Metab . 2016;
101(12): 4719-4729. doi:
10.1210/jc.2016-2711
- Were FN & Lifschitz C. Complementary feeding: beyond nutrition.Ann Nutr Metab . 2018; 73(1): 20-25. doi: 10.1159/000490084